Biogen Inc. (BIIB)

199.65
NASDAQ
Prev Close 193.09
Day Low/High 194.50 / 199.78
52 Wk Low/High 187.16 / 468.55
Exchange NASDAQ
Shares Outstanding 146.45B
Market Cap 28.28B
P/E Ratio 8.89
Div & Yield N.A. (N.A)
Where to Buy in 2014: Part II

Where to Buy in 2014: Part II

Here are four more themes where you can put money to work.

Time to Reconsider Sector Weights

Time to Reconsider Sector Weights

Rather than follow the crowd, I want to lead it.

Big Pharma Emerges From the Wilderness

Big Pharma Emerges From the Wilderness

These four names are soaring, and I'd jump into all of them, even after their recent runs.

Credit Suisse Healthcare Conf.

Cramer: The Top-Calling Finally Arrives

Cramer: The Top-Calling Finally Arrives

Apparently it's 'bad' now that the public has stopped pulling reams of money out of the market.

Watch the Charts on Biogen Idec

Watch the Charts on Biogen Idec

 Timing cycles suggest reversal of BIIB's recent decline.

Searching for Pockets of Strength

Searching for Pockets of Strength

The market is richly priced right now, but you can still find bargains.

Merck, Biogen Kick Off Fed Week

Merck, Biogen Kick Off Fed Week

Biogen and Merck earnings emerge as investors wait for the Federal Reserve's latest policy-making statement.

Understanding the Highflying Stocks

Understanding the Highflying Stocks

When forces line up against them, they tend to fall hard.

Do Not Read This, Herb

Do Not Read This, Herb

It's best for Mr. Greenberg to avert his eyes.

Cramer: Anointed Stocks to Buy

Cramer: Anointed Stocks to Buy

Jim Cramer looks at the top performers of 2013 that should surge into the end of the year, with Mad Money Research Director Nicole Urken.

Off the Charts

Off the Charts

Due to two non-economic factors, the Fed may not taper until 2014.

Off the Charts

Off the Charts

Watch short-term pivots for effect of today's move.

Off the Charts

Off the Charts

Pare down risk in some excess long positions.

Off the Charts

Off the Charts

Use 1684 as your short-term point of reference and keep taking trades in light  volume.

Pounce on the Anointed Ones

Pounce on the Anointed Ones

These stocks look bound to get bought at every dip through year-end. You should buy up, too -- but wait for that swoon.

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.

A Possible Secondary Entry in Biogen

A Possible Secondary Entry in Biogen

If the rally does resume, I see a target around $255.

Biogen Idec numbers upped at BMO

Early-Morning Market Look

Let's take a peek at the price action overnight and in the early morning in the more important asset classes. The rundown: S&P futures down 9 handles; Nikkei down 1.15%; European markets down -- a lot of earnings disappointments overnight, including...

Daily Recap of the Charts, July 19

Daily Recap of the Charts, July 19

John Darsie of T3Live review the day's market action and sets up your trading plan for the next session.

The Real Tech Boom Is Under Way

The Real Tech Boom Is Under Way

This sector offers the best growth opportunity over the next decade.

Analysis: SPY, USO, GS, BIIB & AWAY

Analysis: SPY, USO, GS, BIIB & AWAY

Henry Gambell of Simpler Options steps in for John Carter noting levels we're looking to take profits on SPY and USO along with analysis on GS, BIIB & AWAY.

Playing the Biotechs

There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...

Morning Call, June 27

Morning Call, June 27

Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.

Off the Charts

Off the Charts

Could snapback be the result of end-of-quarter window dressing?

Off the Charts

Off the Charts

The S&P is currently in no-man's land.